Glucose effects in an ovarian cancer protocol of exceptional activity

D. E. Scheim, Jeffrey Lin

Research output: Contribution to journalArticle

Abstract

A French multidrug protocol for stage III ovarian cancer has achieved 77% pathologic complete response, 100% total response, and 81% actuarial 4-year survival. Our analysis indicates that these rates exceed typical with very high statistical significance. Yet neither the drugs, the combined intravenous and intraperitoneal mode of delivery, nor potential bias in the predominantly suboptimal patient population appear to explain the protocol's exceptional results. Here we propose that the atypical administration of intraperitoneal glucose prior to drugs underlies the unusual activity of this protocol. We review studies demonstrating that high-dose glucose has pronounced effects on cancer cells, most notably, substantial potentiation of certain antineoplastic agents. We consider possible mechanisms of such glucose potentiation, including hypothesized osmotic effects that would be especially strong under intraperitoneal administration. We conclude that the French ovarian cancer protocol may represent a significant advance and that glucose potentiation may be more widely applicable as an adjunct to cancer chemotherapy.

Original languageEnglish (US)
Pages (from-to)235-244
Number of pages10
JournalMedical Hypotheses
Volume40
Issue number4
DOIs
StatePublished - Jan 1 1993
Externally publishedYes

Fingerprint

Ovarian Neoplasms
Glucose
Pharmaceutical Preparations
Antineoplastic Agents
Neoplasms
Drug Therapy
Survival
Population

ASJC Scopus subject areas

  • Medicine(all)

Cite this

Glucose effects in an ovarian cancer protocol of exceptional activity. / Scheim, D. E.; Lin, Jeffrey.

In: Medical Hypotheses, Vol. 40, No. 4, 01.01.1993, p. 235-244.

Research output: Contribution to journalArticle

@article{e7b98d7a04d64d61994b43ec6f802574,
title = "Glucose effects in an ovarian cancer protocol of exceptional activity",
abstract = "A French multidrug protocol for stage III ovarian cancer has achieved 77{\%} pathologic complete response, 100{\%} total response, and 81{\%} actuarial 4-year survival. Our analysis indicates that these rates exceed typical with very high statistical significance. Yet neither the drugs, the combined intravenous and intraperitoneal mode of delivery, nor potential bias in the predominantly suboptimal patient population appear to explain the protocol's exceptional results. Here we propose that the atypical administration of intraperitoneal glucose prior to drugs underlies the unusual activity of this protocol. We review studies demonstrating that high-dose glucose has pronounced effects on cancer cells, most notably, substantial potentiation of certain antineoplastic agents. We consider possible mechanisms of such glucose potentiation, including hypothesized osmotic effects that would be especially strong under intraperitoneal administration. We conclude that the French ovarian cancer protocol may represent a significant advance and that glucose potentiation may be more widely applicable as an adjunct to cancer chemotherapy.",
author = "Scheim, {D. E.} and Jeffrey Lin",
year = "1993",
month = "1",
day = "1",
doi = "10.1016/0306-9877(93)90048-U",
language = "English (US)",
volume = "40",
pages = "235--244",
journal = "Medical Hypotheses",
issn = "0306-9877",
publisher = "Churchill Livingstone",
number = "4",

}

TY - JOUR

T1 - Glucose effects in an ovarian cancer protocol of exceptional activity

AU - Scheim, D. E.

AU - Lin, Jeffrey

PY - 1993/1/1

Y1 - 1993/1/1

N2 - A French multidrug protocol for stage III ovarian cancer has achieved 77% pathologic complete response, 100% total response, and 81% actuarial 4-year survival. Our analysis indicates that these rates exceed typical with very high statistical significance. Yet neither the drugs, the combined intravenous and intraperitoneal mode of delivery, nor potential bias in the predominantly suboptimal patient population appear to explain the protocol's exceptional results. Here we propose that the atypical administration of intraperitoneal glucose prior to drugs underlies the unusual activity of this protocol. We review studies demonstrating that high-dose glucose has pronounced effects on cancer cells, most notably, substantial potentiation of certain antineoplastic agents. We consider possible mechanisms of such glucose potentiation, including hypothesized osmotic effects that would be especially strong under intraperitoneal administration. We conclude that the French ovarian cancer protocol may represent a significant advance and that glucose potentiation may be more widely applicable as an adjunct to cancer chemotherapy.

AB - A French multidrug protocol for stage III ovarian cancer has achieved 77% pathologic complete response, 100% total response, and 81% actuarial 4-year survival. Our analysis indicates that these rates exceed typical with very high statistical significance. Yet neither the drugs, the combined intravenous and intraperitoneal mode of delivery, nor potential bias in the predominantly suboptimal patient population appear to explain the protocol's exceptional results. Here we propose that the atypical administration of intraperitoneal glucose prior to drugs underlies the unusual activity of this protocol. We review studies demonstrating that high-dose glucose has pronounced effects on cancer cells, most notably, substantial potentiation of certain antineoplastic agents. We consider possible mechanisms of such glucose potentiation, including hypothesized osmotic effects that would be especially strong under intraperitoneal administration. We conclude that the French ovarian cancer protocol may represent a significant advance and that glucose potentiation may be more widely applicable as an adjunct to cancer chemotherapy.

UR - http://www.scopus.com/inward/record.url?scp=0027212543&partnerID=8YFLogxK

UR - http://www.scopus.com/inward/citedby.url?scp=0027212543&partnerID=8YFLogxK

U2 - 10.1016/0306-9877(93)90048-U

DO - 10.1016/0306-9877(93)90048-U

M3 - Article

C2 - 7686614

AN - SCOPUS:0027212543

VL - 40

SP - 235

EP - 244

JO - Medical Hypotheses

JF - Medical Hypotheses

SN - 0306-9877

IS - 4

ER -